In tumors of different origin, where Wnt/CTNNB1 signaling is not involved and ZFP36 is down-regulated, in the absence of specific mutations or epigenetic events (that are not to be excluded), the tumor advantage-conferring TTP silencing can be achieved as a consequence of the deregulated activity of other specific pathways. This evidence concerns the gene CTNNB1 and neoplasm.